Summary
Stryker Corporation reported a strong third quarter for fiscal year 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 11.9% year-over-year, driven by solid performance in both the MedSurg and Neurotechnology, and Orthopaedics and Spine segments, with particularly strong unit volume increases across most product lines. The company also showed improved operational efficiency, with operating income growing faster than net sales. Net earnings per diluted share rose by 20.0% year-over-year. Stryker continued to invest in growth through strategic acquisitions and development, while also managing its financial leverage effectively through debt issuance and managing cash flow from operations. Investors should note the company's ongoing focus on innovation and strategic M&A as key drivers of future performance, alongside the management's confidence in its financial health and ability to meet liquidity needs.
Financial Highlights
52 data points| Revenue | $5.49B |
| Cost of Revenue | $1.98B |
| Gross Profit | $3.52B |
| R&D Expenses | $377.00M |
| SG&A Expenses | $1.89B |
| Operating Expenses | $2.43B |
| Operating Income | $1.08B |
| Interest Expense | $98.00M |
| Net Income | $834.00M |
| EPS (Basic) | $2.18 |
| EPS (Diluted) | $2.16 |
| Shares Outstanding (Basic) | 381.10M |
| Shares Outstanding (Diluted) | 385.60M |
Key Highlights
- 1Stryker reported a 11.9% increase in net sales for Q3 2024, reaching $5,494 million, with organic growth (excluding acquisitions/divestitures and currency impacts) of 10.3% in constant currency.
- 2Net earnings increased by 20.5% to $834 million for the quarter, with diluted EPS growing 20.0% to $2.16.
- 3Operating income grew by 16.5% to $1,085 million, indicating improved operational leverage as operating income margin expanded to 19.7% from 19.0% in the prior year.
- 4The MedSurg and Neurotechnology segment saw sales growth of 12.8%, while Orthopaedics and Spine grew by 10.7%, showcasing broad-based strength.
- 5The company completed significant acquisitions in the first nine months of 2024, with a total consideration of $1,598 million, net of cash acquired, demonstrating continued M&A activity to expand product portfolios.
- 6Stryker maintained a strong balance sheet with $3,850 million in cash and cash equivalents and $750 million in short-term investments, and ended the quarter with current assets exceeding current liabilities by $7,004 million.
- 7The company issued new senior unsecured notes totaling $1.5 billion and €1.4 billion in September 2024, strengthening its financial position and extending debt maturities.